Cancer Pharmacy Workforce

Dear BOPA members 
 
Many of you may have noted the various workforce publications that have circulated recently.  As a committee we wanted to assure all members that BOPA has endeavoured to push for changes in any publications that we felt were not a true representation of the profession.   
 

  • The first publication was via Health Education England and was specific to Cancer (Dec17).  There was a rapid turnaround on responses for this and Geoff Saunders responded on behalf of BOPA – twe have circulated via email a copy of response Geoff submitted on behalf of BOPA response during the consultation period.   

 

  • A second HEE publication around workforce that detailed the full pharmacy workforce has been in consultation recently and as a committee we provided our views within the consultation period. 

 

 
We hope that you can use the attached and the CRUK document to drive change in workforce within your Trusts or Alliances.  
 
We now have a GAP  (Guidelines, Advocacy and Publications) committee that is dedicated to advocacy activities, this will ensure that wider consultation is achieved for any future publications.  
 
One final thing to note is that despite our best efforts in replying to consultation we have seen a trend for pharmacists to be not given enough priority in the final documents on cancer workforce, the focus is very much still on doctors and nurses. 
 
So our challenge for all our members is for you all to respond from your own organisation – the more pharmacy respondents there are in workforce consultations the better!!
 
Best Wishes
 
Steve Williamson on behalf of BOPA Exec Committee
 
 

Latest News

By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article
By BOPA IO SAG on 23rd April 2025

Toolkit for Immunotherapy IV to SC switch

Dear all, In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however,…

Read article
By BOPA E&T subcommittee on 17th April 2025

The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back

BOPA are holding a nine month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS. Join in this relaxed forum to discuss about your portfolio…

Read article
By BOPA research subcommittee on 17th April 2025

Celebration of BOPA member’s recent publications

We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then…

Read article